Lineage withdraws CIRM grant app for OPC1; plans resubmission Jan 2026

Lineage Cell Therapeutics, Inc.

Withdrew CIRM CLIN2 grant application on Nov 28 after receiving CIRM comments on Nov 24.
No content deficiencies identified; intends to submit revised application in next CIRM cycle (Jan 2026).
Withdrawal does not impact ongoing DOSED clinical study of OPC1 for spinal cord injury.

item 8.01

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-302552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.